Hikma Expectations Stabilize – But Generics Still Set To Take A Hit
Firm Cites ‘Strong Momentum’ For Injectables And Branded Divisions
Executive Summary
After multiple cuts to its Generics guidance earlier this year, Hikma has reiterated its expectations for the company’s full-year results, citing momentum for the firm’s Injectables and Branded segments as well as promising that growth is on the horizon for Generics in 2023.